This recombinant monoclonal antibody is a research-grade biosimilar to RO-7496353, designed to specifically target transforming growth factor beta 1 (TGFB1). TGFB1 is a multifunctional cytokine that plays critical roles in regulating cell proliferation, differentiation, immune responses, and extracellular matrix production. As a key mediator of tissue fibrosis and immune suppression within the tumor microenvironment, TGFB1 has been implicated in numerous pathological conditions including cancer progression, metastasis, fibrotic diseases, and immune evasion. Aberrant TGFB1 signaling contributes to epithelial-mesenchymal transition and creates an immunosuppressive milieu that facilitates tumor growth and therapeutic resistance.
RO-7496353 represents an investigational therapeutic antibody developed to selectively inhibit TGFB1 activity, particularly in the context of oncology research. This biosimilar provides researchers with a valuable tool for investigating TGFB1-mediated pathways, studying tumor-immune interactions, exploring fibrotic mechanisms, and evaluating potential therapeutic strategies targeting the TGF-beta signaling axis in various disease models.
Email: support@cusabio.com
Distributors Worldwide